Icon Plc $ICLR Shares Sold by Eagle Health Investments LP

Eagle Health Investments LP lowered its position in Icon Plc (NASDAQ:ICLR) by 10.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 182,590 shares of the medical research company’s stock after selling 20,200 shares during the period. Icon makes up approximately 8.4% of Eagle Health Investments LP’s investment portfolio, making the stock its 4th largest holding. Eagle Health Investments LP owned 0.23% of Icon worth $31,953,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Geneos Wealth Management Inc. increased its stake in shares of Icon by 11.5% in the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after acquiring an additional 56 shares during the period. Spire Wealth Management lifted its position in Icon by 10.1% during the third quarter. Spire Wealth Management now owns 678 shares of the medical research company’s stock valued at $119,000 after purchasing an additional 62 shares during the period. Mutual Advisors LLC boosted its holdings in Icon by 3.6% in the second quarter. Mutual Advisors LLC now owns 2,698 shares of the medical research company’s stock valued at $392,000 after purchasing an additional 93 shares during the last quarter. Private Trust Co. NA grew its position in Icon by 200.0% during the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock worth $25,000 after purchasing an additional 94 shares during the period. Finally, Sierra Legacy Group raised its stake in shares of Icon by 2.5% during the 3rd quarter. Sierra Legacy Group now owns 4,540 shares of the medical research company’s stock valued at $794,000 after buying an additional 110 shares during the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. UBS Group set a $220.00 target price on Icon in a research note on Friday, October 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Icon in a report on Monday, December 29th. Bank of America reaffirmed an “underperform” rating and set a $75.00 price objective on shares of Icon in a research note on Thursday, February 12th. Rothschild & Co Redburn set a $100.00 target price on shares of Icon and gave the company a “neutral” rating in a research note on Tuesday. Finally, Leerink Partners restated a “market perform” rating and set a $105.00 price target on shares of Icon in a research report on Thursday, February 12th. Four analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $164.33.

Icon Price Performance

Shares of Icon stock opened at $88.62 on Wednesday. The stock has a market capitalization of $7.16 billion, a P/E ratio of 11.99, a PEG ratio of 1.96 and a beta of 1.27. The business has a 50 day simple moving average of $172.29 and a two-hundred day simple moving average of $173.74. Icon Plc has a 12 month low of $66.57 and a 12 month high of $211.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.